# A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

> **NCT03840200** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 51 (actual)

## Conditions studied

- Breast Cancer
- Prostate Cancer
- Ovarian Cancer

## Interventions

- **DRUG:** Ipatasertib
- **DRUG:** Rucaparib

## Key facts

- **NCT ID:** NCT03840200
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-12
- **Primary completion:** 2021-12-07
- **Final completion:** 2022-01-04
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2023-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03840200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03840200, "A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03840200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*